Author: Ken Dropiewski

ConcertAI’s TeraRecon, in Us2.AI Partnership, Integrates AI-Enabled Echocardiography Decision Support into Eureka Clinical AI Platform

The Industry’s leading AI SaaS solution for Acute Cardiac Care bringing critical patient insights to patients’ care teams faster. CAMBRIDGE, Mass., Feb. 24, 2023 /PRNewswire/ — ConcertAI’s TeraRecon Eureka Clinical AI SaaS platform brings artificial intelligence (AI) and Deep Learning technologies to fully automate a complete echocardiography or heart ultrasound report.  Us2.ai’s FDA-cleared and CE Marked echocardiogram […]

Penumbra, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results

ALAMEDA, Calif., Feb. 23, 2023 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2022. Financial Highlights: Revenue of $221.2 million for the fourth quarter of 2022, an increase of 8.4% compared to revenue of $204.0 million for the fourth quarter […]

LeMaitre Q4 2022 Financial Results

BURLINGTON, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) — LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today reported Q4 2022 results, announced a $0.14/share quarterly dividend (+12%) and provided guidance. Q4 2022 Financial Results Sales $41.0mm, +4% (+8% organic) vs. Q4 2021 Op. income $7.0mm, -16% Op. margin […]

iRhythm Technologies Announces Fourth Quarter and Full Year 2022 Financial Results

SAN FRANCISCO, Feb. 23, 2023 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2022. Fourth Quarter 2022 Financial Highlights Revenue of […]

Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office

New Patent Adds to the Istaroxime Patent Estate and Provides Intellectual Property Protection Until Late 2039 WARRINGTON, Pa., Feb. 24, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for cardiovascular disorders, today announced that the United […]

FEops HEARTguide Proven to Significantly Enhance Efficiency and Outcomes of LAA Closure Procedures

GENT, Belgium–(BUSINESS WIRE)–Today, FEops announced the publication of the PREDICT-LAA study in JACC: Cardiovascular Interventions, showing that Left Atrial Appendage Closure (LAAC) procedures planned by means of FEops HEARTguide™ resulted in significant improvement of procedural efficiency and outcomes. Prof. Dr. Ole De Backer (Copenhagen, Denmark), Principal Investigator of this study, […]

Eko Launches SENSORA™ Cardiac Disease Detection Platform

Enterprise-grade digital stethoscope platform brings non-invasive heart disease detection to primary care OAKLAND, Calif., Feb. 23, 2023 /PRNewswire/ — Eko, a digital health company applying artificial intelligence (AI) in the fight against heart and lung disease, today announced the launch of the SENSORA™ Cardiac Disease Detection Platform. SENSORA™ currently features AI that objectively identifies structural […]

Transmural Systems Electrosurgical Guidewire System (TELLTALE) Used in First Procedure in United States in IDE Pivotal Study

ANDOVER, Mass., Feb. 23, 2023 /PRNewswire/ — Transmural Systems the leader in transcatheter electrosurgery for structural interventions announced today successful first-in-human procedure with its TELLTALE electrosurgical guidewire system. The TELLTALE Guidewire System is the first and only dedicated electrosurgical solution to simplify the BASILICA-TAVR procedure for transcatheter traversal and laceration of native […]

TransMedics Reports Fourth Quarter and Full Year 2022 Financial Results

ANDOVER, Mass., Feb. 22, 2023 /PRNewswire/ – TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2022. Recent Highlights  Total revenue of $31.4 million in the fourth quarter […]

Aerami Therapeutics Announces Expansion of the AER-901 (inhaled imatinib) Development Program in Pulmonary Hypertension Supported by Phase 1 Clinical Trial Data and Continued Progress

Expansion of the AER-901 development program to include pulmonary hypertension associated with interstitial lung disease (PH-ILD) builds on the company’s existing program in pulmonary arterial hypertension (PAH) PH-ILD shares clinical and pathophysiological features with PAH, however, there is only one currently approved therapy in PH-ILD and unmet need remains high […]